- Home
- CRGX vs NDMO Comparison
CRGX vs NDMO Comparison
Compare CRGX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- NDMO
- Stock Information
- Founded
- CRGX 2021
- NDMO 2019
- Country
- CRGX United States
- NDMO United States
- Employees
- CRGX N/A
- NDMO N/A
- Industry
- CRGX
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- CRGX
- NDMO Finance
- Exchange
- CRGX Nasdaq
- NDMO Nasdaq
- Market Cap
- CRGX 190.0M
- NDMO N/A
- IPO Year
- CRGX 2023
- NDMO N/A
- Fundamental
- Price
- CRGX $4.60
- NDMO $10.19
- Analyst Decision
- CRGX Hold
- NDMO
- Analyst Count
- CRGX 7
- NDMO 0
- Target Price
- CRGX $5.33
- NDMO N/A
- AVG Volume (30 Days)
- CRGX 1.5M
- NDMO 218.6K
- Earning Date
- CRGX 08-11-2025
- NDMO 01-01-0001
- Dividend Yield
- CRGX N/A
- NDMO 6.75%
- EPS Growth
- CRGX N/A
- NDMO N/A
- EPS
- CRGX N/A
- NDMO N/A
- Revenue
- CRGX N/A
- NDMO N/A
- Revenue This Year
- CRGX $57.81
- NDMO N/A
- Revenue Next Year
- CRGX N/A
- NDMO N/A
- P/E Ratio
- CRGX N/A
- NDMO N/A
- Revenue Growth
- CRGX N/A
- NDMO N/A
- 52 Week Low
- CRGX $3.00
- NDMO $8.99
- 52 Week High
- CRGX $25.45
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- CRGX 62.02
- NDMO 57.74
- Support Level
- CRGX $4.32
- NDMO $10.07
- Resistance Level
- CRGX $4.75
- NDMO $10.28
- Average True Range (ATR)
- CRGX 0.18
- NDMO 0.10
- MACD
- CRGX 0.03
- NDMO 0.01
- Stochastic Oscillator
- CRGX 77.17
- NDMO 71.21
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.